Almirall gets in on the eczema action

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall wants a piece of the action.

Sanofi ups revenues forecasts as eczema drug Dupixent surges

Sanofi has upped its revenue forecasts for the year on the back of strong second quarter results from its new eczema and asthma injection Dupixent and its rare diseases and vaccines busines

Sanofi licenses OTC Tamiflu rights for the US market

German court blocks Sanofi's cholesterol drug after Amgen la...

Amgen has lived up to its litigious reputation after it successfully persuaded a German court to uphold a patent blocking Sanofi from marketing its rival injected cholesterol drug in the co

GSK hires former Genentech expert for AI unit

FDA reviews Sanofi's multiple myeloma drug isatuximab

The FDA has begun its review of Sanofi’s multiple myeloma drug isatuximab, as the French pharma prepares for a tussle with Johnson & Johnson’s blockbuster Darzalex.